Ramaswamy’s Enzyvant scores a double-barreled FDA commitment to help hustle a rare disease drug through its BLA
Love him or hate him — and there are plenty of people in both camps — Vivek Ramaswamy’s companies move fast.
Just a little more than three months ago Enzyvant, Ramaswamy’s rare disease biotech, in-licensed an experimental drug for extraordinarily rare cases of complete DiGeorge Syndrome from Duke University, with eyes already firmly focused on a biologics marketing application for the newly dubbed RVT-802.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
